Objective This study aimed to examine the role of long non-coding RNA PCED1B antisense RNA 1(PCED1B-AS1)in the development of hepatocellular carcinoma(HCC).Methods A total of 62 pairs of HCC tissues and adjacent non-t...Objective This study aimed to examine the role of long non-coding RNA PCED1B antisense RNA 1(PCED1B-AS1)in the development of hepatocellular carcinoma(HCC).Methods A total of 62 pairs of HCC tissues and adjacent non-tumor tissues were obtained from 62 HCC patients.The interactions of PCED1B-AS1 and microRNA-34a(miR-34a)were detected by dual luciferase activity assay and RNA pull-down assay.The RNA expression levels of PCED1B-AS1,miR-34a and CD44 were detected by RT-qPCR,and the protein expression level of CD44 was determined by Western blotting.The cell proliferation was detected by cell proliferation assay,and the cell invasion and migration by transwell invasion assay.The HCC tumor growth after PCED1B-AS1 was downregulated was determined by in vivo animal study.Results PCED1B-AS1 was highly expressed in HCC tissues,which was associated with poor survival of HCC patients.Furthermore,PCED1B-AS1 interacted with miR-34a in HCC cells,but they did not regulate the expression of each other.Additionally,PCED1B-AS1 increased the expression level of CD44,which was targeted by miR-34a.The cell proliferation and invasion assay revealed that miR-34a inhibited the proliferation and invasion of HCC in vitro,while CD44 exhibited the opposite effects.Furthermore,PCED1B-AS1 suppressed the role of miR-34a.Moreover,the knockdown of PCED1B-AS1 repressed the HCC tumor growth in nude mice in vivo.Conclusion PCED1B-AS1 may play an oncogenic role by regulating the miR-34a/CD44 axis in HCC.展开更多
Background:Stool-based molecular markers have shown potential as a strategy for colorectal cancer(CRC)screening.This study aimed to evaluate the feasibility of using microRNA-92a expression as a biomarker for CRC in s...Background:Stool-based molecular markers have shown potential as a strategy for colorectal cancer(CRC)screening.This study aimed to evaluate the feasibility of using microRNA-92a expression as a biomarker for CRC in stool samples.Methods:The level of microRNA-92a was measured in stool samples from 210 CRC patients,29 patients with advanced adenomas,15 patients with other cancers,and 101 healthy controls,using real-time quantitative polymerase chain reaction.Receiver operating characteristic curves were used to evaluate sensitivity and specificity.Results:MicroRNA-92a expression was positive in 70.1%of CRC patients,44.8%of advanced adenomas patients,and 36.6%of healthy controls,using a cut-off value of 31.5.The corresponding sensitivity and specificity for discriminating CRC from advanced adenomas were 66.9%and 63.4%,respectively.Moreover,stool-based microRNA-92a expression was better at detecting CRC cancers in the distal colon(sensitivity 82.1%)than the proximal colon(sensitivity 67.9%).There were no significant differences in clinical stage of CRC when comparing AUCs of each parameter(P>0.05).Conclusion:These findings suggest that microRNA-92a expression in stool samples could serve as a promising non-invasive biomarker for CRC detection.展开更多
目的研究miR-21在弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达,探讨miR-21表达与DL-BCL临床病理特征的关系及其在DLBCL发生发展中的意义。方法采用Real-time RT-PCR方法检测36例DLBCL和10例正常淋巴结中miR-21的表...目的研究miR-21在弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达,探讨miR-21表达与DL-BCL临床病理特征的关系及其在DLBCL发生发展中的意义。方法采用Real-time RT-PCR方法检测36例DLBCL和10例正常淋巴结中miR-21的表达,并采用免疫组织化学SP法检测Ki-67、PTEN在DLBCL中的表达。结果miR-21在DLBCL中高表达,36例DLBCL中有14例表达PTEN(38.9%),21例Ki-67≥50%(58.3%)。DLBCL中miR-21表达水平与PTEN蛋白表达呈负相关,其高表达与DLBCL高Ann Arbor分期、高增殖指数(Ki-67≥50%)、国际预后指数(IPI)呈正相关。结论miR-21过表达可能是DLBCL恶性度高的标志,是促进DLBCL肿瘤细胞增殖的重要因素。PTEN可能是miR-21在DLBCL发挥作用的靶标。展开更多
基金supported by the Medical Science and Technology Research Foundation of Guangdong Province(No.A2020559).
文摘Objective This study aimed to examine the role of long non-coding RNA PCED1B antisense RNA 1(PCED1B-AS1)in the development of hepatocellular carcinoma(HCC).Methods A total of 62 pairs of HCC tissues and adjacent non-tumor tissues were obtained from 62 HCC patients.The interactions of PCED1B-AS1 and microRNA-34a(miR-34a)were detected by dual luciferase activity assay and RNA pull-down assay.The RNA expression levels of PCED1B-AS1,miR-34a and CD44 were detected by RT-qPCR,and the protein expression level of CD44 was determined by Western blotting.The cell proliferation was detected by cell proliferation assay,and the cell invasion and migration by transwell invasion assay.The HCC tumor growth after PCED1B-AS1 was downregulated was determined by in vivo animal study.Results PCED1B-AS1 was highly expressed in HCC tissues,which was associated with poor survival of HCC patients.Furthermore,PCED1B-AS1 interacted with miR-34a in HCC cells,but they did not regulate the expression of each other.Additionally,PCED1B-AS1 increased the expression level of CD44,which was targeted by miR-34a.The cell proliferation and invasion assay revealed that miR-34a inhibited the proliferation and invasion of HCC in vitro,while CD44 exhibited the opposite effects.Furthermore,PCED1B-AS1 suppressed the role of miR-34a.Moreover,the knockdown of PCED1B-AS1 repressed the HCC tumor growth in nude mice in vivo.Conclusion PCED1B-AS1 may play an oncogenic role by regulating the miR-34a/CD44 axis in HCC.
基金This study was supported by the National Natural Science Foundation of China(Grant No.82202907 to Rong-Bin Liu).
文摘Background:Stool-based molecular markers have shown potential as a strategy for colorectal cancer(CRC)screening.This study aimed to evaluate the feasibility of using microRNA-92a expression as a biomarker for CRC in stool samples.Methods:The level of microRNA-92a was measured in stool samples from 210 CRC patients,29 patients with advanced adenomas,15 patients with other cancers,and 101 healthy controls,using real-time quantitative polymerase chain reaction.Receiver operating characteristic curves were used to evaluate sensitivity and specificity.Results:MicroRNA-92a expression was positive in 70.1%of CRC patients,44.8%of advanced adenomas patients,and 36.6%of healthy controls,using a cut-off value of 31.5.The corresponding sensitivity and specificity for discriminating CRC from advanced adenomas were 66.9%and 63.4%,respectively.Moreover,stool-based microRNA-92a expression was better at detecting CRC cancers in the distal colon(sensitivity 82.1%)than the proximal colon(sensitivity 67.9%).There were no significant differences in clinical stage of CRC when comparing AUCs of each parameter(P>0.05).Conclusion:These findings suggest that microRNA-92a expression in stool samples could serve as a promising non-invasive biomarker for CRC detection.
